The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Kaken’s Hyperhidrosis Drug Ecclock Gets Approval in South Korea
Kaken Pharmaceutical said on September 2 that South Korean regulators have approved its primary axillary hyperhidrosis treatment Ecclock (sofpironium bromide), with the launch planned once preparations are complete. The approval was granted to local partner Dong-Wha Pharm, which obtained the…
To read the full story
Related Article
- Hyperhidrosis Drug Ecclock Filed in South Korea: Kaken
October 6, 2023
- Kaken, Dong-Wha Ink License Pact for Ecclock in South Korea
June 6, 2023
BUSINESS
- Meiji Restarts Domestic 6-APA Production after 31-Year Hiatus
January 5, 2026
- Meiji Files NDA for Nacubactam in Japan
January 5, 2026
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- SymBio Bags Rights to Develop Antiviral Brincidofovir for Alzheimer’s
December 26, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…